MA44608A - Récepteurs des lymphocytes t - Google Patents
Récepteurs des lymphocytes tInfo
- Publication number
- MA44608A MA44608A MA044608A MA44608A MA44608A MA 44608 A MA44608 A MA 44608A MA 044608 A MA044608 A MA 044608A MA 44608 A MA44608 A MA 44608A MA 44608 A MA44608 A MA 44608A
- Authority
- MA
- Morocco
- Prior art keywords
- lymphocyte receptors
- lymphocyte
- receptors
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201606009 | 2016-04-08 | ||
PCT/GB2017/050985 WO2017175006A1 (fr) | 2016-04-08 | 2017-04-07 | Récepteurs des lymphocytes t |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44608A true MA44608A (fr) | 2019-02-13 |
MA44608B1 MA44608B1 (fr) | 2022-06-30 |
Family
ID=58548761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44608A MA44608B1 (fr) | 2016-04-08 | 2017-04-07 | Récepteurs des lymphocytes t |
Country Status (29)
Country | Link |
---|---|
US (2) | US11505590B2 (fr) |
EP (2) | EP3440105B1 (fr) |
JP (1) | JP7254519B2 (fr) |
KR (1) | KR102473964B1 (fr) |
CN (1) | CN109563148B (fr) |
AU (2) | AU2017246693B2 (fr) |
BR (1) | BR112018070741A2 (fr) |
CA (1) | CA3020214A1 (fr) |
CL (1) | CL2018002859A1 (fr) |
CO (1) | CO2018011972A2 (fr) |
CR (1) | CR20180531A (fr) |
DK (1) | DK3440105T3 (fr) |
ES (1) | ES2914648T3 (fr) |
HR (1) | HRP20220865T1 (fr) |
HU (1) | HUE059159T2 (fr) |
IL (2) | IL308831A (fr) |
LT (1) | LT3440105T (fr) |
MA (1) | MA44608B1 (fr) |
MD (1) | MD3440105T2 (fr) |
MX (1) | MX2018012318A (fr) |
MY (1) | MY198621A (fr) |
PE (2) | PE20240693A1 (fr) |
PH (1) | PH12018502158A1 (fr) |
PL (1) | PL3440105T3 (fr) |
PT (1) | PT3440105T (fr) |
RS (1) | RS63371B1 (fr) |
SG (1) | SG11201808797XA (fr) |
SI (1) | SI3440105T1 (fr) |
WO (1) | WO2017175006A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3020530A1 (fr) * | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | Recepteurs de lymphocytes t |
JP7204484B2 (ja) | 2016-04-08 | 2023-01-16 | アダプティミューン・リミテッド | T細胞受容体 |
MX2020003536A (es) | 2017-10-03 | 2020-09-14 | Juno Therapeutics Inc | Moleculas de union especifica a virus de papiloma humano (hpv). |
WO2019133443A1 (fr) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Récepteurs de lymphocytes t modifiés |
GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
BR112020020245A2 (pt) * | 2018-04-05 | 2021-04-06 | Editas Medicine, Inc. | Métodos de produzir células expressando um receptor recombinante e composições relacionadas |
HRP20240176T1 (hr) | 2019-01-17 | 2024-04-12 | Immunocore Limited | Formulacije |
GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
EP3714941A1 (fr) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Récepteurs de lymphocytes t de mage-a4 |
EP3986938A4 (fr) * | 2019-06-18 | 2023-06-28 | Regeneron Pharmaceuticals, Inc. | Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation |
EP3990476A1 (fr) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
AU2020406085A1 (en) | 2019-12-18 | 2022-05-26 | F. Hoffmann-La Roche Ag | Antibodies binding to HLA-A2/MAGE-A4 |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
JP2023528255A (ja) * | 2020-05-18 | 2023-07-04 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 操作されたt細胞受容体および使用の方法 |
CA3183756A1 (fr) * | 2020-05-19 | 2021-11-25 | Amgen Inc. | Constructions de liaison a mageb2 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
AU2022233285A1 (en) | 2021-03-09 | 2023-10-19 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
WO2023076983A1 (fr) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Dérivés de pyridine-3(2h)-one |
CA3235986A1 (fr) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Composes cd73 |
TW202328212A (zh) | 2021-12-01 | 2023-07-16 | 英商英美偌科有限公司 | Mage—a4陽性癌症之治療 |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术(广东)有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
WO2024038183A1 (fr) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Molécules de liaison à domaines multiples |
WO2024038165A1 (fr) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | Protéines de fusion de récepteurs de lymphocytes t spécifiques de mage a4 |
WO2024038198A1 (fr) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Molécules de liaison à domaines multiples |
WO2024038193A1 (fr) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Molécules de liaison à domaines multiples |
US20240091262A1 (en) * | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖t細胞レセプタータンパク質 |
US6710172B1 (en) | 1998-10-02 | 2004-03-23 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
DK1247095T3 (da) | 1999-12-06 | 2008-12-08 | Univ Illinois | TCR-proteiner med höj affinitet samt fremgangsmåder |
EP1259601A2 (fr) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Banques d'affichage de phages chimeriques et tcr, reactifs chimeriques et tcr et methodes d'utilisation correspondantes |
DE60203125T2 (de) | 2001-08-31 | 2006-04-06 | Avidex Ltd., Abingdon | Löslicher t zell rezeptor |
AU2003289716A1 (en) * | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
ATE432290T1 (de) | 2002-11-09 | 2009-06-15 | Immunocore Ltd | T ZELL REZEPTOR ßDISPLAYß |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
EP2301964A1 (fr) | 2005-04-01 | 2011-03-30 | Immunocore Ltd. | Récepteurs de lymphocytes T infectés par le VIH présentant une affinité élevée |
KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | T 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
CA2848209C (fr) | 2011-09-15 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recepteurs des lymphocytes t reconnaissant un gene mage restreint par hla-a1 ou hla-cw7 |
EP2766042A4 (fr) * | 2011-10-14 | 2015-05-27 | Teva Pharmaceuticals Australia Pty Ltd | ANTICORPS DIRIGÉS CONTRE LA CD1d |
AU2012327204B2 (en) | 2011-10-28 | 2016-01-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified T cell receptor mice |
GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
EP3747899A3 (fr) | 2013-01-29 | 2021-02-24 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Molécules de liaison à avidité élevée reconnaissant mage-a1 |
EP2971045B1 (fr) | 2013-03-13 | 2019-06-19 | Health Research, Inc. | Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral |
WO2016007570A2 (fr) | 2014-07-09 | 2016-01-14 | The Regents Of The University Of California | Lymphocytes t tueurs naturels invariants (inkt) génétiquement modifiés procédés de production et d'utilisation de ceux-ci |
CN107074970B (zh) | 2014-08-04 | 2021-07-30 | 弗雷德哈钦森癌症研究中心 | 特异性针对wt-1的t细胞免疫疗法 |
CN114149511A (zh) | 2015-04-13 | 2022-03-08 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
ES2968802T3 (es) | 2016-03-16 | 2024-05-14 | Immatics Biotechnologies Gmbh | Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer |
SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
-
2017
- 2017-04-07 KR KR1020187032374A patent/KR102473964B1/ko active IP Right Grant
- 2017-04-07 IL IL308831A patent/IL308831A/en unknown
- 2017-04-07 SG SG11201808797XA patent/SG11201808797XA/en unknown
- 2017-04-07 PL PL17717845.6T patent/PL3440105T3/pl unknown
- 2017-04-07 CN CN201780035758.0A patent/CN109563148B/zh active Active
- 2017-04-07 PE PE2023002239A patent/PE20240693A1/es unknown
- 2017-04-07 BR BR112018070741-4A patent/BR112018070741A2/pt unknown
- 2017-04-07 CR CR20180531A patent/CR20180531A/es unknown
- 2017-04-07 IL IL262144A patent/IL262144B2/en unknown
- 2017-04-07 AU AU2017246693A patent/AU2017246693B2/en active Active
- 2017-04-07 RS RS20220652A patent/RS63371B1/sr unknown
- 2017-04-07 EP EP17717845.6A patent/EP3440105B1/fr active Active
- 2017-04-07 LT LTEPPCT/GB2017/050985T patent/LT3440105T/lt unknown
- 2017-04-07 MY MYPI2018001690A patent/MY198621A/en unknown
- 2017-04-07 DK DK17717845.6T patent/DK3440105T3/da active
- 2017-04-07 MA MA44608A patent/MA44608B1/fr unknown
- 2017-04-07 CA CA3020214A patent/CA3020214A1/fr active Pending
- 2017-04-07 HU HUE17717845A patent/HUE059159T2/hu unknown
- 2017-04-07 JP JP2018552859A patent/JP7254519B2/ja active Active
- 2017-04-07 PT PT177178456T patent/PT3440105T/pt unknown
- 2017-04-07 ES ES17717845T patent/ES2914648T3/es active Active
- 2017-04-07 WO PCT/GB2017/050985 patent/WO2017175006A1/fr active Application Filing
- 2017-04-07 US US16/092,174 patent/US11505590B2/en active Active
- 2017-04-07 MX MX2018012318A patent/MX2018012318A/es unknown
- 2017-04-07 EP EP21211000.1A patent/EP4023668A1/fr active Pending
- 2017-04-07 PE PE2018001971A patent/PE20190335A1/es unknown
- 2017-04-07 SI SI201731151T patent/SI3440105T1/sl unknown
- 2017-04-07 HR HRP20220865TT patent/HRP20220865T1/hr unknown
- 2017-04-07 MD MDE20190184T patent/MD3440105T2/ro unknown
-
2018
- 2018-10-08 PH PH12018502158A patent/PH12018502158A1/en unknown
- 2018-10-08 CL CL2018002859A patent/CL2018002859A1/es unknown
- 2018-11-02 CO CONC2018/0011972A patent/CO2018011972A2/es unknown
-
2022
- 2022-10-13 US US18/046,408 patent/US20230322895A1/en active Pending
- 2022-10-19 AU AU2022256131A patent/AU2022256131A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44608A (fr) | Récepteurs des lymphocytes t | |
DK3440106T3 (da) | T-cellereceptorer | |
DK3494133T3 (da) | Anti-kras-g12d-t-cellereceptorer | |
DK3642224T3 (da) | T-cellereceptorer | |
MA47359A (fr) | Récepteurs de lymphocytes t à appariement amélioré | |
UA39812S (uk) | Мотоцикл | |
DK3394094T3 (da) | T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset | |
DK3448882T3 (da) | Anti-kk-lc-1-t-cellereceptorer | |
DK3628687T3 (da) | Kimære bcma-antigenreceptorer | |
CL2018003441S1 (es) | Motocicleta | |
DK3216994T3 (da) | Længdeskyllet totaktsmotor | |
DK3449990T3 (da) | Separationsindretning | |
DK3703482T3 (da) | Adskillelsesindretning | |
DK3127860T3 (da) | Sadeldækken | |
DK3329056T3 (da) | Adskillelsesanordning | |
UA39306S (uk) | Мотокоса | |
UY4677S (es) | Motocicleta | |
UA38733S (uk) | Мотокоса | |
UA38586S (uk) | Мотокоса | |
UA39170S (uk) | Мотокоса | |
UA38613S (uk) | Мотокоса | |
UA38510S (uk) | Мотоцикл | |
UA37563S (uk) | Мотоцикл | |
UA38085S (uk) | Мотоцикл | |
UA37722S (uk) | Мотоцикл |